2025

1. Lara-Castor L, O’Hearn M, Cudhea, et al. Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries. Nature Medicine. January 2025
2. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology Commission. January 14, 2025
3. Misra A, Vikram NK, Ghosh A, et al. Revised definition of obesity in Asian Indians living in India. Diabetes & Metabolic Syndrome Clinical Research & Reviews 2025
4. Misra A, Kumar A, Kuchay MS, et al. Consensus guidelines for the diagnosis and management of metabolic dysfunction associated steatotic liver disease in adults Asian Indians with type 2 diabetes. Diabetes & Metabolic Syndrome Clinical Research & Reviews 2025
5. Gulati S, Misra A. Premeal load of macronutrients as an effective nutritional strategy to control postprandial glycemia. Clinical Diabetology. 2025
6. Lee MMY, Ghouri N, Misra A et al. Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in Asian versus White Populations: Systematic review and meta-analysis of randomized trials of populations with or without type 2 diabetes and/or overweight or obesity.  Diabetes Care 2025;48:489–493
7. Nassar M, Nassar O, Abosheaishaa H, Misra A. Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network :Author list. J Endocrinol Invest. 2025 Feb;48(2):483-497
8. Vaishya R, Misra A, Nassar M, et al. Respiratory sarcopenia: A scoping review of the current literature. International Journal of Diabetes in Developing Countries. Feb.2025
9. Ramachandran A, Nanditha A, Tuomilehto J, etal. A. Call to action for clinicians in the South-East Asian regions on primary prevention of diabetes in people with prediabetes- A consensus statement. Diabetes Res Clin Pract. 2025 Mar;221:111997
10. Nassar M, Abosheaishaa H, Misra A, et al. Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis. Diabetes Metab. 2025 Mar;51(2):101613
11. Parikh RM, Saboo B, Misra A, et al. Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia. Diabetes Metab Syndr. 2025 Feb;19(2):103205
12. Vaishya R, Misra A, Patralekh MK, et al. Association of type 2 diabetes and osteoarthritis: an umbrella review of systematic reviews and meta-analyses. Eur J Orthop Surg Traumatol. 2025 Mar 12;35(1):111
13. Singh A, Singh AK, Singh R, et al. Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials. Diabetes Metab Syndr. 2025 Mar 8;19(3):103212
14. Vaishya R, Vaish A, Misra A. Critical review of “Normative values of grip and pinch strength and their predictor factors: PERSIAN cohort study of healthcare staff”. Int Orthop. 2025 Mar 28
15. Vaishya R, Misra A, Singla R, et al. Influence of COVID- 19 pandemic on impact factors of top biomedical journals. Ir J Med Sci. 2025 Apr 12
16. Vaishya R, Patralekh MK, Misra A, et al. Outcomes of total knee arthroplasty in people with diabetes: An overview of systematic reviews and meta-analysis. J Orthop Res. 2025
17. Misra A, Sattar N, Ghosh A,et al.Type 2 diabetes in South Asians.BMJ. 2025 Aug 12;390:e079801
18. Sattar N, Misra A.Adiposity at the core of the rising tide of young-onset type 2 diabetes worldwide.Diabetes Metab Syndr. 2025 May;19(5):103249
19. Misra A. Rational application of weight loss therapies according to new obesity guidelines in Asian Indians: A perspective for low-income settings. Diabetes Metab Syndr. 2025 Apr;19(4):103226
20. Misra A, Joshi S, Mithal A.Malnutrition-related diabetes mellitus: Rushing toward “type 5” amid unresolved questions and limited evidence.Diabetes Metab Syndr. 2025 May;19(5):103250
21. Nassar M, Abosheaishaa H, Elfert K, et al. TriNetX and real-world evidence: A critical review of its strengths, limitations, and bias considerations in clinical research. ASIDE Intern Med. 2025 Apr;1(2):24-33
22. Kehar S, Bhatt SP, Pandey RM, et al. Glycemic, lipid, anthropometric and body composition responses to two Mango varieties versus white bread in people with type 2 diabetes: an 8-week randomised controlled trial.J Diabetes Metab Disord. 2025 Aug 2;24(2):183
23. Bhatt SP, Pandey S, Misra A. Independent effects of vitamin D on leukocyte telomere length and activity: A RCT in Asian Indian women with prediabetes. Journal of the Endocrine Society Aug 2025
24. Ghosh A, Misra A. From abdominal adiposity to liver fibrosis: Expanding promise of semaglutide for Asian Indians. Indian J Gastroenterol. 2025 Oct 10
25. Misra A, Sharma S. BMI lower than 23 kg/m²is better for screening of diabetes and cardiovascular risk in Asian Indians?: Clinical and research implications of emerging data. Diabetes Metab Syndr. 2025 Sep 24;19(8):103301
26. Hassan A, Keshk MA, Reyad M, et. al. Bridging the gap between evidence and practice: Nationwide retrospective analysis of lipid-modifying therapy prescription patterns in 5 million patients with type 2 diabetes mellitus. ASIDE Intern Med. 2026 Apr 1;2(2):6-11
27. Kehar S, Bhatt SP, Pandey RM, et al. Glycemic responses of three mango varieties in subjects with and without T2D: a pilot crossover study using OTT and CGM. Eur J Clin Nutr. 2025 Sep 13
28. Misra A, Gupta R. Intermittent fasting: Evidence for benefit, lack of effect, or potential cardiometabolic risk? Diabetes Metab Syndr. 2025 Jul;19(7):103280.
29. Misra A, Anoop S, Sharma S. Obesity, abdominal obesity, and adipose tissue depots in South Asians with specific reference to Asian Indians: Implications of New Obesity Guidelines. J Clin Lipidol. 2025 Jul 21:S1933-2874(25)00327-7
30. Adebisi YA, Ngoma C, Campagna D, et al. Differential associations between smoking, e-cigarette use, and diabetes prevalence. Diabetes Metab Syndr. 2025 Oct;19(10):103331
31. Dutta D, Kamrul-Hasan ABM, Jena S, et al. Impact of sodium-glucose co-transporter-2 inhibitor combined with mineralocorticoid receptor antagonist therapy versus either agent alone in individuals with chronic kidney disease: A systematic review and meta-analysis. Diabetes Metab Syndr. 2025 Nov;19(11):103334
32. Vaishya R, Misra A, Vaish A.Scientific writing in the age of artificial intelligence: trust on trial?Postgrad Med J. 2025 Dec 23:qgaf215
33. Kumar A, Kuchay MS, Ghosh A, et al. India-Specific Consensus on MASLD in Type 2 Diabetes: Bridging Global Guidelines to Local Realities. Diabetes Care. 2025 Nov 1;48(11):e153-e154
34. Gulati S, Misra A, Tiwari R, et al Effect of supplementation with n-trans caffeoyltyramine and n-trans feruloyltyramine on glycemia in prediabetic individuals: Randomized, double-blind, placebo-controlled trial. Bioactive Compounds in Health and Disease 2025; 8(11)
35. Vaishya R, Misra A, Gupta BM, et al. Rising trends in pediatric type 2 diabetes: A comprehensive bibliometric analysis of global research (1998-2023). J Nepal Med Assoc 2025;63(282):1-5

2024

1. Nassar M, Misra A and Bloomgarden Z. Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database.J Diabetes. 2024 Mar;16(3):e13547.
2. Dutta K, Bhatt SP, Madan S, et al. Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India.Prim Care Diabetes. 2024 Apr;18(2):224-229.
3. Vaishya R, Misra A,Vaish A, Ursino N, D’Ambrosi R. Hand grip strength as a proposed new vital sign of health: a narrative review of evidences. J Health Popul Nutr. 2024 Jan 9;43(1):7.
4. Nassar M, Nassar O, Abosheaishaa H, Misra A. Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network. September 2024. Journal of Endocrinological Investigation.
5. Nassar M, Nassar O, Abosheaishaa H, Misra A. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: apropensity-matchedglobal federated TriNetX database-based retrospective cohort study. Diabetes Metab Syndr. 2024 Sep 19;18.
6. Kesavadev J, Misra A, Das AK, Saboo B. Vaccination in diabetes: updated guidelines for 2024. August 2024. International Journal of Diabetes and Technology 3(2):61-73.
7. Zhou XD, Chen QF, Targher G, et al.  Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15-39, 1990-2021. Clinical Nutrition. 14 November 2024.
8. Zhang H, Zhou XD, Shapiro MD, et al. Global burden of metabolic diseases, 1990-2021. 2024 Nov:160:155999.
9. Vaishya R, Gupta BM, Mamdapur GMN, Misra A. Scientometricanalysis of global publications on prediabetes and osteoporosis: 1994-2023. Journal of Clinical Orthopaedics and Trauma 54(10169):102493.
10. Singh AK, Singh R, Singh A, Misra A. Efficacy and safety of oral semaglutide in type 2 diabetes: asystematic review of real-world evidence. May 2024. Diabetes & Metabolic Syndrome Clinical Research & Reviews 18(5).
11. Kuchay MS, Isaacs S, Misra A. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom. Diabetes Metab Syndr. 2024 May;18(5):103034
12. Zhang L, El-Shabrawi M, Baur LA, et al. An international multidisciplinary consensus on paediatric metabolic dysfunction-associated fatty liver disease. Med. 2024 Jul 12;5(7):797-815.
13. Zeng XF, Varady KA, Wang XD, et al. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism. 2024 Dec;161:156028.
14. Sammut R, Grech J, Polosa R, et al. Behavioral therapy for people with diabetes who Smoke: ascoping review. J Prim Care Community Health. 2024 Jan-Dec.
15. Rutter MK, Carr MJ, Wright AK, et al. Indirect effects of the COVID-19 pandemic on diagnosing, monitoring, and prescribing in people with diabetes and strategies for diabetes service recovery internationally. Diabetes Res Clin Pract. 2024 Jun;212:111693.
16. Walicka M, Krysiński A, La Rosa GRM, et al. Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy. Diabetes Metab Syndr. 2024 May;18(5):103044. 
17. Vaishya R, Gupta BM, Kappi MM, Misra A, Kuchay MS, Vaish A. Research on non-alcoholic fatty liver disease from Indian subcontinent: abibliometric analysis of publications during 2001-2022. J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101271.
18. Zhou XD, Chen QF, Yang H, et al.  Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. EClinicalMedicine. 2024 Sep 24:76:102848.

2023

1. Vaishya R, Gupta BM, Misra A, Mamdapur GMN, Walke R, Vaish A. Top 100 highly cited papers from India on COVID-19 research: A bibliometric analysis of the core literature. Diabetes Metab Syndr. 2023 Nov;17(11):102898.
2. Dutta D, Nagendra L, Bhat S, Mohindra R, Surana V, Misra A. Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials. Diabetes Metab Syndr. 2023 Oct 11;17(10):102877.
3. Lara-Castor L, Micha R, Cudhea F, et al. Global Dietary Database. Sugar-sweetened beverage intakes among adults between 1990 and 2018 in 185 countries. Nat Commun. 2023 Oct 3;14(1):5957.
4. Vaishya R, Misra A. The journal ‘Diabetes and Metabolic Syndrome: Clinical Research and Reviews̕ achieves a double-digit impact factor, marking its ascent. Diabetes Metab Syndr. 2023 Aug;17(8):102830.
5. Singh AK, Singh A, Singh R, Joshi SR, Misra A. Non-sugar sweeteners and health outcomes in adults without diabetes: deciphering the WHO recommendations in the Indian context. Diabetes Metab Syndr. 2023 Jul 8;17(8):102829.
6. Kumari A, Ranjan P, Vikram NK, et al. Evidence and consensus-based clinical practice guideline for the management of obesity and overweight in postpartum women: An AIIMS-DST initiative. J Family Med Prim Care. 2023 May;12(5):812-855.
7. Vaishya R, Misra A, Vaish A, Singh SK. Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges. J Diabetes. 2023 Jun 8.
8. Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023 May 19:1–19.
9. Vaishya R, Misra A, Vaish A. ChatGPT: Is this version good for healthcare and research? Diabetes Metab Syndr. 2023 Apr;17(4):102744. Epub 2023 Mar 15.
10. Meenakshi S, Misra A. Effect of dates on blood glucose and other metabolic variables: A narrative review. Diabetes Metab Syndr. 2023 Feb;17(2):102705.
11. Gulati S, Misra A, Tiwari R, et al. Premeal almond load decreases postprandial glycaemia, adiposity and reversed prediabetes to normoglycemia: A randomized controlled trial. Clin Nutr ESPEN. 2023 Apr;54:12-22. Epub 2022 Dec 29.
12. Gulati S, Misra A, Tiwari R, et al. Beneficial effects of premeal almond load on glucose profile on oral glucose tolerance and continuous glucose monitoring: randomized crossover trials in Asian Indians with prediabetes. Eur J Clin Nutr. 2023 May;77(5):586-595. Epub 2023 Feb 2.
13. Nishi SK, Viguiliouk E, Kendall CWC, et al. Nuts in the prevention and management of type 2 diabetes. Nutrients. 2023 Feb 9;15(4):878.
14. Ranjan P, Vikram NK, Kumari A, et al. Evidence and consensus-based clinical practice guidelines for management of overweight and obesity in midlife women: An AIIMS-DST initiative. J Family Med Prim Care. 2022 Dec;11(12):7549-7601.
15. Nassar M, Abosheaishaa H, Singh AK, Misra A. Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. J Diabetes. 2023 Jan 23.
16. Dutta D, Mohindra R, Misra A Comment on: “efficacy and safety of saroglitazar in patients with cardiometabolic diseases: asystematic review and meta-analysis of randomized controlled trials”. Clin Drug Investig.2023;42(12):1049-1064.
17. Singh AK, Singh A, Singh R, Misra A. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metab Syndr. 2023 Jan 20;17(2):102710.
18. O’Hearn M, Lara-Castor L, Cudhea F, et al. Incident type 2 diabetes attributable to suboptimal diet in 184 countries. Nature Medicine.Volume 29.April 2023.982–995.
19. Mohan V, Misra A, Bhansali A, et al. Role and significance of dietary protein in the management of type 2 diabetes and its complications in India: an expert opinion. J Assoc Physicians India. 2023 Dec;71(12):36-46.
20. Singh AK, Misra A, Das AK, et al. SGLT2i as a first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: asystematic review and consensus. J Assoc Physicians India. 2023 Dec;71(12):62-74.
21. Tyagi K, Madan S, Bhatt SP, Ansari IA, Dutta K, Misra A. Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: a retrospective study. Clin Nutr ESPEN. 2023 Oct:57:305-310.
22. Meena K, Misra A, Vikram N, Ali S, Upadhyay AD, Luthra K. Genetic polymorphism of fatty acid binding protein-2 in hyperlipidemic Asian Indians in North India. Am J Hum Biol. 2023 Mar;35(3):e23834.
23. Dutta K, Bhatt SP, Ghosh A, Gupta R, Tyagi K, Ansari IA. Metformin and dapagliflozin decrease fetuin A, hepatic &pancreatic fat and hepatic fibrosis in Asian Indians with type 2 diabetes. Researchsquare. October 2023.
24. Nassar M, Misra A, Bloomgarden Z. COVID-19 Vaccination in persons with diabetes: how they work. Molecular Biology. June 2023. 28536-3_13.
25. Miller V, Webb P, Cudhea F, et al. Children’s and adolescents’ rising animal-source food intakes in 1990-2018 were impacted by age, region, parental education and urbanicity.Nat Food. 2023 Apr;4(4):305-319.
26. Campagna D; DiaSmokeFree Working Group. Comment on Elsayed et al. 5. facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S68-S96.

2022

1. Jayasinghe S, Misra A. Post-COVID-19 syndrome and type 2 diabetes: primacy of exercise in prevention and management. Diabetes Metab Syndr. 2022 Jan;16(1):102379.
2. Kesavadev J, Misra A, Saboo B, et al. Time-in-range and frequency of continuous glucose monitoring: Recommendations for South Asia. Diabetes Metab Syndr. 2022 Jan;16(1):102345.
3. Saboo B, Misra A, Kalra S, et.al. Role and importance of high fiber in diabetes management in India. Diabetes Metab Syndr. 2022 May;16(5):102480.
4. Kuchay MS, Misra A. Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes? Diabetes Metab Syndr. 2022 Aug;16(8):102580.
5. Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022 Feb;16(2):102396.
6. Gargari P, Mukhopadhyay P, Saboo B, et al. Fabkin and glucose homeostasis. Diabetes Metab Syndr. 2022 Aug;16(8):102565
7. Gupta R, Misra A. Hyperlipidemia management in diabetes: first line or supportive therapy? Diabetes Metab Syndr. 2022 Apr;16(4):102470.
8. Nassar M, NsoN, Emmanuel K, et al. Coronary Artery Calcium Score directed risk stratification of patients with Type-2 diabetes mellitus. Diabetes Metab Syndr. 2022 Jun;16(6):102503.
9. Vaishya R, Gupta BM, Misra A, et al. Global research in sarcopenia: high-cited papers, research institutions, funding agencies and collaborations, 1993-2022. Diabetes Metab Syndr. 2022 Nov;16(11):102654.
10. Singh AK, Singh A, Singh R, et al. Finerenone in diabetic kidney disease: a systematic review and critical appraisal. Diabetes Metab Syndr. 2022 Oct;16(10):102638.
11. Singh AK, Singh A, Singh R, et al. Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr. 2022 Sep;16(9):102615.
12. Sachdev M, Misra A. Heterogeneity of dietary practices in India: current status and implications for the prevention and control of type 2 diabetes. Eur J Clin Nutr. 2022 Jan 17
13. Singh AK, Singh R, Misra A. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes Metab Syndr. 2022 Mar;16(3):102436.
14. Kumari A, Ranjan P, Vikram NK, et al. Executive summary of evidence and consensus-based clinical practice guideline for management of obesity and overweight in postpartum women: An AIIMS-DST initiative.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16 (2022) 102425.
15. Ranjan P,Vikram NK,Choranur A, et al. Executive summary of evidence and consensus-based clinical practice guidelinesfor management of obesity and overweight in midlife women: An AIIMS-DST initiative. Diabetes& Metabolic Syndrome: Clinical Research & Reviews 16 (2022) 102426.
16. Kuchay MS, Misra A. Role of diabetologists in the management of non-alcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.Diabetes & Metabolic Syndrome: Clinical Research & Reviews. March 2022, 102446
17. Ghosh A, Dutta K, Bhatt SP, et al. Dapagliflozin improves body fat patterning, and hepatic and pancreatic fat in patients with type 2 diabetes in North India. The Journal of Clinical Endocrinology & Metabolism. March 2022.
18. Chadha M, Das AK, Deb P, et al. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting.Diabetes Therapy. March 2022.
19. Sabharwal M, Misra A, Ghosh A, et al. Efficacy of digitally supported and real-time self-monitoring of blood glucose-driven counselling in patients with type 2 diabetes mellitus: areal-world, retrospective study in North India. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume. January 2022.
20. Miller V, Webb P, Cudhea F, et al.Global dietary quality in 185 countries from 1990 to 2018 show wide differences by nation, age, education, and urbanicity. Nat Food. 2022 Sep;3(9):694-702.
21. Misra P, Jha S, Misra A, Kant S.Reporting of randomized controlled trials as per CONSORT guidelines.J Family Med Prim Care. 2022 Oct;11(10):6598.
22. Miller V, Reedy J, Cudhea F, et al. Global, regional, and national consumption of animal-source foods between 1990 and 2018: findings from the Global Dietary Database.Lancet Planet Health. 2022 Mar;6(3):e243-e256.
23. Jayasinghe S, Misra A, Hills AP. Post-COVID-19 syndrome and type 2 diabetes: Primacy of exercise in prevention and management. Diabetes Metab Syndr. 2022 Jan;16(1):102379.
24. Vaishya R, Misra A.International rankings of Diabetes and Metabolic diseases related journals in comparison to other medical journals from India.Diabetes Metab Syndr. 2022 Jul;16(7):102559.
25. Kumar V, Agarwal S, Saboo B, Makkar B, et al. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. International Journal of Diabetes in Developing Countries. January 2023.

2021

1. Misra A. Majorly resurgent and uncontrolled diabetes during COVID19 era in India can be contained. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.S1871-4021(21)00153-3.
2. Ranasinghe P, Jayawardena R, Gamage N, Sivanandam N, Misra A. Prevalence and trends of the diabetes epidemic in Urban and Rural India: a pooled systematic review and meta-analysis of 1.7 million adults. Ann Epidemiol.2021 Jun;58:128-148.
3. Sosale A,Sosale B, Kesavadev J, el al. Steroid use during COVID-19 infection and hyperglycemia – What a Physician should know.Diabetes & Metabolic Syndrome: Clinical Research & ReviewsS1871-4021(21)00185-5.
4. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes and Metabolic Syndrome Clinical Research and Reviews. May 2021.
5. Pal R, Bhadada SK, Misra A. Resurgence of COVID-19 and diabetes in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 1037e1038.
6. Ghosh A, Anjana RM, Rani CSS, et al. Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 215e220.
7. Kesavadev J, Misra A, Saboo B, et al. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 221e227.
8. Misra A, Ghosh A, Gupta R. Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: a proposed classification.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 403e406.
9. Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 505e508.
10. Mohan V, at al. Type 2 diabetes in the young in South Asia: clinical heterogeneity and need for aggressive public health measures. Journal of Diabetes. 2021;1–3.
11. Mishra A, Misra A, Bloomgarden Z. Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: report of three cases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. S1871-4021(21)00162-4.
12. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 1007e1008.
13. Gopalan S, Haque I, Ahmad S, Gaur A, Misra A. Education and screening for obesity, hypertension, and diabetes (including gestational diabetes) “at the doorstep” of women from nine underprivileged urban areas in Delhi National Capital Region. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021)102209.
14. Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021 Jun 23;11(1):2.
15. Sarveswaran G, RangamaniS, Ghosh A, et al. Management of diabetes mellitus through tele consultation during COVID-19 and similar scenarios: guidelines from Indian Council of Medical Research (ICMR) expert group.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021)102242.
16. Singh AK, Singh R, Saboo B, Misra A. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a Critical Appraisal of Literature.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 159e167.
17. Ghosh A, Misra A. Marked hyperglycemia and ketosis in a non-obese patient with new onset diabetes and very mild COVID-19 symptoms: a case report. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 213e214.
18. Raveendran AV, Misra A. Post COVID-19 Syndrome (“Long COVID”) and Diabetes: challenges in diagnosis and management.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021)102235.
19. Jayawardena R, Jeyakumar DT, Francis TV, Misra A.Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 757e764.
20. Singh AK, Singh R, Misra A. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction? Journal of Diabetes. 2021;1–5.
21. Sharma M, Aggarwal S, Nayar U, Vikram NK, Misra A, Luthra K. Differential expression of insulin receptor substrate-1(IRS-1) in visceral and subcutaneous adipose depots of morbidly obese subjects undergoing bariatric surgery in a tertiary care centre in north India; SNP analysis and correlation with metabolic profile. Diabetes MetabSyndrMay-Jun 2021;15(3):981-986.
22. Mulakavalupil B, Vaity C, Joshi S, Misra A, Pandit RA. Absence of Case of Mucormycosis under strict protocol-driven management care in a COVID-19 specific tertiary care intensive care unit. Diabetes and Metabolic Syndrome Clinical Research and Reviews. May 2021.
23. Misra P, Kant S, Misra A, et al. A community based randomized controlled trial to see the effect of vitamin D supplementation on development of diabetes among women with prediabetes residing in a rural community of Northern India. Family Med Prim Care. 2021 Aug.
24. Jayawardena R, Swarnamali H, Ranasinghe P, Misra A.Health effects of coconut oil: Summary of evidence from systematic reviews and meta-analysis of interventional studies. Diabetes and Metabolic Syndrome Clinical Research and Reviews15(2) March 2021.
25. Moreira NC et al. Race/ethnicity and challenges for optimal insulin therapy. April 2021.Diabetes Research and Clinical Practice April 2021.
26. Sosale A, Sosale B, Kesavadev J, et al. Steroid use during COVID-19 infection and hyperglycemia – What a physician should know. Diabetes and Metabolic Syndrome Clinical Research and Reviews 15(170). June 2021.
27. Nassar M, Daoud A, Nso N, et al. Diabetes mellitus and COVID-19: review article. Diabetes and Metabolic Syndrome Clinical Research and Reviews 15(13):102268.September 2021.
28. Nanditha A, Raghavan A, Misra A, et al. Management of hyperglycemia in COVID-19 and post-COVID-19 syndrome- proposed guidelines for India. The Journal of the Association of Physicians of India 69(9).September 2021
29. Mittal J, GhoshA, Bhatt SP, Anoop S, Ansari IA, Misra A. High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: a case-control study.Diabetes and Metabolic Syndrome Clinical Research and Reviews 15(5):102302. September 2021
30. Gupta A, Anoop S, Ansari IA, Prakash S, Misra A. High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus. Clinical Nutrition ESPEN 46(5).September 2021
31. Bhatt SP, Misra A, Pandey RM, Upadhyay AD. Shortening of leucocyte telomerase length is independently correlated with high body mass index and subcutaneous obesity (Predominantly Truncal), in Asian Indian women with prediabetes. Research Square. September 2021
32. Jayawardena R, Sooriyaarachchi P, Misra A. Abdominal obesity and metabolic syndrome in South Asians: prevention and management. Expert Review of Endocrinology & Metabolism 16(7121).September 2021.
33. Misra A, Ramachandran A, Saboo B,et al. Screening for diabetes in India should be initiated at 25 years age. Diabetes and Metabolic Syndrome Clinical Research and Reviews 15(12):102321. October 2021
34. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: a systematic reviewof literature. Diabetes and Metabolic Syndrome Clinical Research and Reviews 15(37):102329
35. Bansal M, Misra A.Cardiovascular disease and diabetes in South Asians: the twin epidemic.Curr Diabetes Rev. 2021;17(9):e122820189512. 
36. Kesavadev J, Misra A, Saboo B, et al. Reply to the letter of Draves et al. In response to the article: “Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization” (Kesavadev et al.)”.Diabetes Metab Syndr. 2021 Jan-Feb;15(1):466

2020

1. Misra A. Dietary cholesterol advisory from American Heart Association: implications for India and other developing countries. Diabetes Metab Syndr. 2020 Mar – Apr;14(2):107-8.
2. Luthra A, Misra A. Escalating cost of oral and injectable antihyperglycemic drugs; are newer medications worth their price? a perspective from India and other developing countries. Diabetes Metab Syndr, 2020. 14(2): p. 167-169.
3. Kehar S, Misra A. Mango: A fruit too far in patients with diabetes? (or is it?). Diabetes Metab Syndr, 2020. 14(2): p. 135-136.
4. Bhatt SP, Misra A, Pandey RM, Upadhayay AD, Gulati S, Singh N. Vitamin D supplementation in overweight/obese Asian Indian women with prediabetes reduces glycemic measures and truncal subcutaneous fat: a 78 weeks randomized placebo-controlled trial (PREVENT-WIN Trial). Sci Rep, 2020. 10(1): p. 220.
5. Gulati S, Misra A, Tiwari R, Sharma M, Pandey RM, Upadhayay AD. The influence of polymorphisms of fat mass and obesity (FTO, rs9939609) and vitamin D receptor (VDR, BsmI, TaqI, ApaI, FokI) genes on weight loss by diet and exercise interventions in non-diabetic overweight/obese Asian Indians in North India. Eur J Clin Nutr, 2020.
6. Misra A. Dietary cholesterol advisory from American Heart Association: implications for India and other developing countries. Diabetes Metab Syndr, 2020. 14(2): p. 107-108.
7. Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians. Diabetes Metab Syndr. 2020 Apr 4;14(4):273-6
8. Bhatt SP, Misra A, Pandey RM. rs7903146 (C/T) polymorphism of Transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians. Diabetes Metab Syndr. 2020 Feb 21;14(3):175-80.
9. Gupta R, Ghosh A, Singh AK, Misra A. Diabetes considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 Mar 10;14(3):211-2.
10. Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A. Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases. Diabetes Res Clin Pract. 2020 Mar 26;162:108127.
11. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (hypertension, diabetes etc). Diabetes Metab Syndr. 2020 Mar 25;14(3):251-4.
12. Jha A, Misra A, Gupta R,et al. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: a series of 13 cases. Diabetes Metab Syndr. 2020 Mar 4;14(3):213-6.
13. Misra A. Doctors and healthcare workers at frontline of COVID 19 epidemic: admiration, a pat on the back, and need for extreme caution. Diabetes Metab Syndr. 2020 Mar 22;14(3):255-6.
14. Misra A. Diabetes-related research in India and other south Asian countries is inadequate requiring more funding, coaching and structure. Diabetes Metab Syndr. 2020 Mar – Apr;14(2):171-2.
15. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020 Apr 9;14(4):303-10.
16. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin-angiotensin system blockers. Diabetes Metab Syndr. 2020 Apr 9;14(4):283-7.
17. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020 Mar 26;14(3):241-6.
18. Ghosal S, Sinha B, Majumder M, Misra A. Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020 Apr 10;14(4):319-23.
19. Gopalan H, Misra A. Innovations and proactive political commitment are required to combat diabetes in India and other developing countries. Diabetes Metab Syndr, 2020. 14(1): p. 39-41.
20. Misra A. Way forward for the Journal in times of escalating challenges. Diabetes Metab Syndr, 2020. 14(1): p. 43.
21. Gopalan HS, Misra A. COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India. Diabetes Metab Syndr. 2020 May 30;14(5):757-9.
22. Ghosh A, Arora B, Gupta R, Anoop S, Misra A. Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020 Jun 2;14(5):917-20.
23. Ghosal S, Arora B, Dutta K, Ghosh A, Sinha B, Misra A. Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: a cohort analysis. Diabetes Metab Syndr. 2020 Jun 19;14(5):949-52.
24. Diabetes, National Diabetes Obesity Cholesterol, Foundation, Diabetes Expert Group, India. Strict glycemic control is needed in times of COVID19 epidemic in India: acall for action for all physicians. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14 (2020) 1579e1581.
25. Diabetes, National Diabetes Obesity Cholesterol, Foundation Nutrition Expert Group, India. Balanced nutrition is needed in times of COVID19 epidemic in India: a call for action for all nutritionists and physicians. Diabetes Metab Syndr. 2020;14(6):1747-50.
26. Singh AK, Singh A, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr.Jul-Aug 2020;14(4):641-648.
27. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr Sep-Oct 2020;14(5):971-978.
28. Singh AK, Singh A, Singh R, Misra A. Hydroxychloroquine in patients with COVID-19: asystematic review and meta-analysis. Diabetes Metab Syndr Jul-Aug 2020;14(4):589-596.
29. Gupta R, Hussain A, Misra A. Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr. 2020 Jun;74(6):864-870.
30. Singh AK, Misra A. Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India. Diabetes Metab Syndr.Jul-Aug 2020;14(4):497.
31. Jayawardena R, Ranasinghe P, Ranawaka H, Gamage N, Dissanayake D, Misra A. Exploring the therapeutic benefits of pranayama (yogic breathing): asystematic review. Int J Yoga. 2020 May-Aug;13(2):99-110.
32. Jayawardena R, Misra A. Balanced diet is a major casualty in COVID-19. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1085-1086.
33. Misra A, Bloomgarden Z. Diabetes during the COVID-19 pandemic: a global call to reconnect with patients and emphasize lifestyle changes and optimize glycemic and blood pressure control. J Diabetes. 2020 Jul;12(7):556-557.
34. Martinez-Amezcua P, Haque W, Khera R, et al. The upcoming epidemic of heart failure in South Asia.Circ Heart Fail. 2020 Oct;13(10):e007218.
35. Unnikrishnan R, Misra A.Infections and diabetes: Risks and mitigation with reference to India.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1889-1894.
36. Kuchay MS, Misra A.From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): a journey over 40 years.Diabetes Metab Syndr. 2020 Jul-Aug;14(4):695-696.
37. Misra A.Sagging original research in diabetes could be boosted if Indian pharmaceutical companies contribute to investigator-initiated hypothesis-driven research.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2231-2232.
38. Misra BB, Misra A.The chemical exposome of type 2 diabetes mellitus: opportunities and challenges in the omics era.Diabetes Metab Syndr. 2020 Jan-Feb;14(1):23-38.
39. Singh AK, Misra A.Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1625-1630.
40. Jayawardena R, Jeyakumar DT, Misra A, Hills AP, Ranasinghe P.Obesity: A potential risk factor for infection and mortality in the current COVID-19 epidemic.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2199-2203
41. Gupta R, Misra A.Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1777-1781.
42. Kuchay MS, Choudhary NS, Mishra SK, Misra A.Non-alcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2233-2239.
43. Ghosh A, Dutta K, Tyagi K, Gupta R, Misra A. Roadblock in application of telemedicine for diabetes management in India during COVID19 pandemic.Diabetes Metab Syndr. 2020 Jul-Aug;14(4):577-578.
44. Gupta R, Misra A. COVID19 in South Asians/Asian Indians: Heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract. 2020 Jul;165:108267.
45. Solanki DK, Walia R, Gautam A, Misra A, Aggarwal AK, Bhansali A.Prevalence of abdominal obesity in non-obese adolescents: a North Indian adolescent study.J Pediatr Endocrinol Metab. 2020 Jul 28;33(7):853-858.
46. Ghosh A, Gupta V, Misra A.COVID19 induced acute pancreatitis and pancreatic necrosis in a patient with type 2 diabetes.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2097-2098.
47. Anoop S, Krakauer J, Krakauer N, Misra A.A Body shape index significantly predicts MRI-defined abdominal adipose tissue depots in non-obese Asian Indians with type 2 diabetes mellitus.BMJ Open Diabetes Res Care. 2020 Oct;8(1):e001324.
48. Gupta R, Tyagi K, Anoop S, Ghosh A, Misra A.About 1/3rd of north Indian patients less than 50 years of age with type 2 diabetes have high pulse wave velocity indicating high risk of atherosclerosis.Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2205-2210.
49. Sharma A, Kumar A, Jha A, Agarwal A, Misra A.The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis – a cross-sectional study.Reumatologia. 2020;58(1):9-14.